eXoZymes selects Curia as commercial-scale manufacturing partner for NCT

• Exozymes entered an agreement with Curia to transfer and scale up manufacturing for N-trans-caffeoyltyramine (NCT).
• Program set to start in Q4 2026, targeting a technical roadmap for larger-scale production in 2027.
• Curia to run scale-up work at facilities in León, Spain, and Rozzano, Italy.
• Collaboration supports planned commercial launch preparation, including customer qualification and future supply agreements for NCT.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.